Patient weighting of osteoporosis medication attributes across racial and ethnic groups: a study of osteoporosis medication preferences using conjoint analysis

@article{Silverman2013PatientWO,
  title={Patient weighting of osteoporosis medication attributes across racial and ethnic groups: a study of osteoporosis medication preferences using conjoint analysis},
  author={Stuart L. Silverman and Andrew D. Calderon and K. Kaw and Trenita B. Childers and Beth A. Stafford and Wendy D. Brynildsen and Augusto Focil and Michael J. Koenig and Deborah T. Gold},
  journal={Osteoporosis International},
  year={2013},
  volume={24},
  pages={2067-2077},
  url={https://api.semanticscholar.org/CorpusID:9974049}
}
The study showed that postmenopausal women differ in the ranking of OP medication attributes based on age, educational level, income, and prior fracture history, and healthcare providers must account for personal preferences in their communication about and selection of OP medications.
View on Springer
ncbi.nlm.nih.gov
36 Citations
Highly Influential Citations
4
Background Citations
8
Methods Citations
2
Results Citations
4

36 Citations

Determining patient preferences for the medical management of osteoporosis using conjoint analysis

Examining patient decision-making surrounding osteoporosis medications using conjoint analysis found that individual patient characteristics and clinical factors did not reliably predict patient decision making, suggesting that development and implementation of shared decision-making tools is warranted.

Understanding patients’ preferences for osteoporosis treatment: the impact of patients’ characteristics on subgroups and latent classes

Summary This study revealed patterns in osteoporosis patients’ treatment preferences, which cannot be related to socio-demographic or clinical characteristics, implicating unknown underlying reasons.…

Stated Preferences of At-Risk Populations for the Treatment of Osteoporosis: A Systematic Review

The readiness of patients to engage in trade-offs between attributes suggests that healthcare providers should ensure treatments are aligned with individual patient preferences to improve adherence and optimize outcomes.

Patients’ preferences for osteoporosis drug treatment: a discrete-choice experiment

This study revealed that osteoporotic patients preferred 6-month subcutaneous injection and oral monthly tablet, and disliked gastro-intestinal disorders, and was willing to pay a personal contribution or to trade treatment efficacy for better levels of other attributes.

Osteoporosis treatment preferences and satisfaction in postmenopausal women: Denosumab compared with oral bisphosphonates

Findings from reviewed studies favor Denosumab over oral bisphosphonates as the preferred long-term treatment in postmenopausal women.

Patients’ preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment

It is found that international treatment recommendations should allow for local adaptation, and that understanding individual preferences is important if the authors want to improve the quality of clinical care for patients with osteoporosis.

A Qualitative Study to Assess US Patient Preferences between new Transdermal System and Injectable Anabolic Therapies for Osteoporosis Treatment

It is revealed that efficacy, safety, costs, and convenience are important attributes of osteoporosis treatment for US patients at high risk for fractures when choosing between anabolic therapies, with a high stated preference for the solid Microstructured Transdermal System.

HEALTH ECONOMICS AND QUALITY OF LIFE (M HARRISON, SECTION EDITOR)

Variations in the preferences of patients were served in most studies, suggesting the importance to take into account individual preference in decision-making to improve osteoporosis care.

Treatment thresholds and minimal clinically important effect sizes of antiosteoporotic medication–Survey among physicians and lay persons in Germany

Lay persons tolerate a higher fracture risk and demand a larger benefit of antiosteoporotic medication for fracture prevention than physicians, who demand higher minimum benefits than their own estimates which in turn are above the benefit evidence suggests.

Methods to Assess Patient Preferences in Old Age Pharmacotherapy – A Systematic Review

To facilitate valid preference elicitation in the context of geriatric polypharmacy, future research should focus on suitable characteristics of existing techniques to develop new measurement approaches for this increasingly relevant population.

18 References

Patient preferences for osteoporosis in Spain: a discrete choice experiment

Spanish osteoporosis patients have well-defined preferences among treatment attributes and are willing to accept trade-offs among attributes, according to a discrete choice experiment.

Preferences of GPs and Patients for Preventive Osteoporosis Drug Treatment

GPs and patients showed different preferences towards preventive osteoporosis drug treatment, and addressing each of these differences may have a positive effect on the process and outcomes of shared decision making regarding preventive treatment initiation.

Racial Disparities in Treatment Preferences for Rheumatoid Arthritis

In this study, fewer black patients preferred aggressive treatment compared with white patients with similar disease severity, which has important clinical implications because use of aggressive treatment improves both short- and long-term outcomes in rheumatoid arthritis.

Understanding why rheumatoid arthritis patient treatment preferences differ by race.

African American patients attach greater importance to the risks of toxicity and less importance toThe likelihood of benefit than their white counterparts, and effective risk communication and improved understanding of expected benefits may help decrease unwanted variability in health care.

Patient treatment preferences for osteoporosis.

Patient preferences for osteoporosis treatment options are strongly influenced by route of administration, and among those preferring bisphosphonates, many preferred annual infusions over weekly oral medications, emphasizing the need to incorporate individual patient preferences into treatment decisions for bone densitometry.

Measuring patient perceptions about osteoporosis pharmacotherapy

The 5-item osteoporosis drug treatment benefits scale may be useful to examine perceptions about the benefits of osteop orosis pharmacotherapy, and should be used as a separate item assessing potential barriers to adherence to osteopOrosis pharmac Therapy.

Women's preferences for prevention of bone loss.

In this CBCA survey, which derived preferences based on how women make tradeoffs between specific treatment characteristics, a significant percentage of women were willing to use once-weekly medications to prevent postmenopausal bone loss.

Beliefs about Prescription Medications among Patients with Diabetes: Variation Across Racial Groups and Influences on Cost-Related Medication Underuse

Differences across racial groups in diabetes patients' medication-related beliefs and adherence problems due to cost concerns are understood, but unknown factors explain higher rates of cost-related adherence problems among African American compared with White patients.

Measuring Patients’ Medical Care Preferences: Care Seeking versus Self-Treating

A scale to measure patient preferences for using medical care, developed and mailed to a random sample of 3500 Wisconsin consumers to assess the reliability and validity of the scale, provided evidence of predictive validity.

Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009

Although less frequent dosing is preferred, other factors such as perceived efficacy, side effects, medication cost, availability of patient support programmes and route of delivery are equally important.